Plain-English fact sheet
Tesamorelin
Also known as Egrifta SV
Tesamorelin is FDA approved for reducing excess abdominal fat in adults with HIV and lipodystrophy, not for general weight loss.
Quick answer
Tesamorelin has a specific FDA-approved use in adults with HIV and lipodystrophy. That narrow approval should not be stretched into a general anti-aging, bodybuilding, or weight-loss claim.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Tesamorelin?
Tesamorelin is a manufactured analog of growth hormone-releasing factor. It signals the pituitary gland and affects the growth-hormone pathway.
Its approved use addresses excess abdominal fat associated with HIV lipodystrophy in adults.
Why are people interested in it?
People sometimes encounter tesamorelin in discussions of body composition, growth hormone, or aging.
Those discussions often omit that FDA approval is limited to a defined HIV-related condition and that the label says it is not indicated for weight-loss management.
Current regulatory status
Egrifta SV is FDA approved to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not indicated for general weight-loss management.
What is it approved for?
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy
What is it being studied for?
Investigational areas
- Other metabolic or liver outcomes studied in defined research settings
Evidence snapshot
Randomized trials support the narrow approved indication. Evidence for unrelated wellness goals is not equivalent.
Potential benefits being researched
- Clinical trials support reduction in visceral abdominal fat for the labeled population.
- That outcome does not establish broad weight-loss, longevity, or performance benefits.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- The label includes contraindications and warnings involving malignancy, pregnancy, elevated IGF-1, glucose intolerance or diabetes, hypersensitivity, and fluid retention.
- Injection-site reactions and musculoskeletal symptoms may occur.
- Effects of long-term treatment on cardiovascular safety have not been established in the label.
What we still do not know
- Long-term cardiovascular outcomes
- Benefits and harms for people outside the approved population
- Whether changes in abdominal fat translate to every outcome a reader may care about
Plain-English takeaway
Tesamorelin is a real approved medicine with a narrow use. Its approval is not evidence for general weight loss, anti-aging, or athletic-performance claims.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA prescribing information: Egrifta SV
Official label describing indication, limitations, and safety information.
- 2FDA Drugs@FDA search: tesamorelin
Official FDA approval records, labels, and regulatory history.
- 3ClinicalTrials.gov studies: tesamorelin
Current and completed registered clinical studies.
- 4PubMed research: tesamorelin HIV lipodystrophy
Peer-reviewed literature indexed by the National Library of Medicine.